Title:
PROTEIN BINDING NKG2D, CD16 AND FIBROBLAST ACTIVATION PROTEIN
Document Type and Number:
Japanese Patent JP2023182838
Kind Code:
A
Abstract:
To provide multi-specific binding proteins that bind to the NKG2D receptor, CD16 receptor and fibroblast activation protein (FAP) and also provide pharmaceutical compositions and therapeutic methods of the multi-specific binding proteins useful for treatment of cancer, autoimmune disease or fibrosis.SOLUTION: The invention provides multi-specific binding proteins that bind to the NKG2D receptor and CD16 receptor on natural killer cells, and the tumor-associated antigen (FAP). Such proteins can engage two or more kinds of NK-activating receptor, and may block the binding of natural ligands to NKG2D.SELECTED DRAWING: None
Inventors:
GREGORY P CHANG
ANN F CHEUNG
DU JINYAN
GRINBERG ASYA
WILLIAM HANEY
NICOLAI WAGTMANN
BRADLEY M LUNDE
BIANKA PRINZ
ANN F CHEUNG
DU JINYAN
GRINBERG ASYA
WILLIAM HANEY
NICOLAI WAGTMANN
BRADLEY M LUNDE
BIANKA PRINZ
Application Number:
JP2023183225A
Publication Date:
December 26, 2023
Filing Date:
October 25, 2023
Export Citation:
Assignee:
DRAGONFLY THERAPEUTICS INC
International Classes:
C07K16/28; A61K39/395; A61P1/00; A61P1/16; A61P5/16; A61P9/00; A61P11/00; A61P13/12; A61P19/02; A61P35/00; A61P37/02; A61P43/00; C07K16/30; C07K16/46; C12N1/15; C12N1/19; C12N1/21; C12N5/0783; C12N5/09; C12N5/10
Attorney, Agent or Firm:
Shusaku Yamamoto
Natsuki Morishita
Takatoshi Iida
Daisuke Ishikawa
Kensaku Yamamoto
Natsuki Morishita
Takatoshi Iida
Daisuke Ishikawa
Kensaku Yamamoto